GREG ZANTE
CIK 1264949 · Chief Financial Officer · last filed 2026-07-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.41M
Companies
3
Total Filings
35
Lifetime Open-Market Net
-$26.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VKTX | Chief Financial Officer | 233,421 | $31.74 | $7.41M | -$26.05M | 17 | 2026-07-29 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Chief Financial Officer | 89,751 | $4.60 | $412.9K | $0 | 2 | 2021-01-19 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | VP, Finance & Administration | 0 | $0.18 | $0 | -$430.0K | 6 | 2008-03-12 |
Recent Filings · Page 3 of 4
35 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-18 | VKTX | Mixed | — | -$52.0K | EDGAR |
| 2023-04-17 | VKTX | Notice (144) | −7,500 | -$150.0K | EDGAR |
| 2023-04-13 | VKTX | Mixed | — | -$1.22M | EDGAR |
| 2023-04-03 | VKTX | Mixed | −35,778 | -$2.83M | EDGAR |
| 2023-01-04 | VKTX | Mixed | +46,562 | -$563.4K | EDGAR |
| 2022-01-05 | VKTX | Mixed | +41,401 | -$55.9K | EDGAR |
| 2021-09-30 | VKTX | Mixed | +4,361 | -$15.0K | EDGAR |
| 2021-01-19 | Viking Therapeutics, Inc. (VKTXW) Delisted | Tax (F) | −808 | -$5.4K | EDGAR |
| 2021-01-06 | Viking Therapeutics, Inc. (VKTXW) Delisted | Mixed | +68,663 | -$16.2K | EDGAR |
| 2008-03-12 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$789 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.